Whalerock Point Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

Whalerock Point Partners’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-32,700	Closed	-$264K	–	155
2016 Q3	$264K	Buy	+32,700	New	+$278K	0.11%	118
2016 Q1	$262K	Hold	34,060	–	–	0.11%	118
2015 Q4	$367K	Sell	34,060 -3,000	-8%	-$27.3K	0.16%	99
2015 Q3	$256K	Hold	37,060	–	–	0.11%	135
2015 Q2	$328K	Hold	37,060	–	–	0.14%	110
2015 Q1	$365K	Buy	37,060 +60	+0.2%	+$749	0.15%	109
2014 Q4	$453K	Buy	37,000 +16,100	+77%	+$197K	0.19%	86
2014 Q3	$208K	Buy	+20,900	New	+$194K	0.09%	143

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Whalerock Point Partners's ACHN Position: Q4 2016 in Review

Whalerock Point Partners sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 32,700 shares — an estimated $264K sold.

Whalerock Point Partners first reported a position in ACHN in Q3 2014 and held it in 8 quarters. The position peaked at $453K in Q4 2014. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

Whalerock Point Partners reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Whalerock Point Partners sold 32,700 Achillion Pharmaceuticals shares in Q4 2016, an estimated $264K.
Whalerock Point Partners first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 8 quarters.
Whalerock Point Partners's Achillion Pharmaceuticals position peaked at $453K in Q4 2014.
140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Whalerock Point Partners's 13F filing for Q4 2016, filed 1 Mar 2017.